Matches 1 - 50 out of 97 1 2 >
Match Document Document Title
7378094 Therapeutic uses of complement receptor 2  
The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune...
7364737 Human neutralizing monoclonal antibodies to respiratory syncytial virus  
Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also...
7341728 Internalisation of virus into cells  
A chimeric transmembrane protein which promotes viral entry into cells comprises: (i) an extracellular domain capable of binding a virus; and (ii) an intracellular internalisation signal.
7294336 Stabilized liquid anti-RSV antibody formulations  
The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which...
7264804 Kits for detecting anti-SIRS antibodies  
The invention includes kits for producing and using immunogenic compositions that include swine infertility and respiratory virus. The invention also includes vaccines and sera for treatment of...
7223844 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by Env-CD4-co-receptor complexes  
The present invention features antibodies and antibody fragments that specifically bind a CD4-inducible HIV gp120 epitope that is enhanced by binding a co-receptor for HIV, such as CCR5 or CXCR4,...
7132100 Stabilized liquid anti-RSV antibody formulations  
The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which...
7115262 Chimeric protein for prevention and treatment of HIV infection  
This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an...
7025970 Modified poxviruses, including modified smallpox virus vaccine based on recombinant drug-sensitive vaccinia virus, and new selection methods  
The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that...
7014847 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders  
The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders,...
6982156 Compositions and methods modulating variola and vaccinia virus  
Antibodies directed to SPICE and VCP which may be used for detection, prevention, and treatment of variola virus or vaccinia virus are provided. Recombinant SPICE and VCP proteins are also provided...
6979534 Compositions and methods for detection of antibody binding to cells  
The invention relates to methods of agglutinating or capturing cells comprising providing a mixture comprising a population of cells and a population of bacteriophage expressing a first antibody on...
6974686 Recombinant tryptophan mutants of influenza  
Recombinant PB2 tryptophan variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such...
6960431 Therapeutic compositions and methods for treating viral infection  
Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a therapeutic peptide or a derivative thereof.
6855315 Kits for detecting swine infertility and respiratory syndrome (SIRS) virus  
The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic “mystery...
6841353 Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue  
Antibodies to two new epitopes on the HCV envelope proteins were identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes...
6824778 Prophylactic and therapeutic monoclonal antibodies  
In this application are described monoclonal antibodies which recognize E3 glycoprotein of alphavirus and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of...
6818216 Anti-RSV antibodies  
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody...
6814964 Supramolecules containing binding and therapeutic molecules bound to hybridized nucleic acids  
A supramolecule has a first supramolecular component including a first effector molecule covalently joined to a first nucleic acid, and a second supramolecular component including a second effector...
6673562 Differential immunoassay  
The invention provides assay methods and kits that in general measure the level of a first analyte in a sample reduced by the level of a second analyte present in the same sample. In one...
6673355 Rotavirus enterotoxin NSP4 and methods of using same  
The rotavirus nonstructural glycoprotein, NSP4, performs multiple functions in the virus replication cycle, especially during viral morphogenesis. Specifically, NSP4 is an intracellular receptor...
6630144 Monoclonal antibodies to Ebola glycoprotein  
In this application are described Ebola GP monoclonal antibodies and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well...
6610473 Peptides for inhibiting HPV E6-proteins  
The present invention relates to peptides suited for inhibiting HPV-E6 proteins, DNAs encoding them and the use of both, particularly for eliminating HPV tumor cells.
6610303 Papilloma viruses, products for the detection thereof as well as for treating diseases caused by them  
This invention relates to a DNA coding for a peptide of a papilloma virus major capsid protein and a papilloma virus genome, respectively. In addition, this invention concerns proteins coded by the...
6610295 Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor  
HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH...
6566095 Compositions and methods for preventing transepithelial transmission of HIV  
Methods, compositions and articles for blocking transepithelial transmission of HIV with ICAM-1 angonist/antagonists are provided. The ICAM-1 agonist/antagonists block viral transmission at the...
6558961 Immunodiagnostics using particle delivery methods  
Methods for assessing immunocompetence, cellular or humoral immunity, antigen exposure, or allergic conditions in an individual by accelerating diagnostic particles into a target skin site in the...
6531127 Antibodies that specifically react with seroreactive regions on HPV 16 proteins E1 and E2  
The invention relates to seroreactive regions on the E1 and E2 proteins of human papillomavirus 16 (HPV 16). The invention also relates to a vaccine that contains peptides comprising at least one...
6528056 Inhibition of viral infection using antigen-binding proteins  
A method of inhibiting viral infection using a monovalent antigen binding protein comprising a single domain binding unit capable of binding to a virus is described. Preferably the protein is a...
6500623 Replication defective HIV vaccine  
A replication-defective HIV particle pseudotyped with vesicular stomatitis virus G protein (VSV-G). The pol gene of the HIV genome in the particle is modified to inactivate the pol reverse...
6465170 Method for depleting viral and molecular pathogens in a biological material  
A method for depleting viral and molecular pathogens in a biological material containing one or several biological substances to be recovered is disclosed, wherein the biological material is...
6464976 Methods and compositions for reducing immune response  
The present invention provides an apparatus and method to diminish the pre-existing immune response to the administration of a therapeutic virus by the selective elimination of antiviral antibodies...
6455245 Mystery swine disease diagnostic kits  
Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions...
6451980 Signal enhancement of bispecific antibody-polymer probe for immunoassay use  
An immunoassay method including reacting a sample from a patient with a bispecific antibody, wherein the bispecific antibody includes one antibody specific for a compound to be detected and a...
6420336 Methods of using cyanovirins topically to inhibit viral infection  
The present invention provides antiviral proteins, peptides and conjugates, as well as methods of obtaining these agents. The antiviral proteins, peptides and conjugates of the present invention...
6413515 Avian, vitelline antibodies directed against HIV antigens  
The present invention is drawn to avian vitellin antibodies that are immunologically reactive with HIV antigens, a process for the preparation thereof, a use thereof and a food substance in the...
6406861 Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration  
Methods of reducing pre-existing humoral immunity to a viral immunogenic therapeutic agent such as adenovirus, using immunoapheresis are disclosed. Antibodies specific for the viral immunogenic...
6403301 Process for detecting Borna disease virus (BDV) infections  
The invention allows, for the first time, to (almost) perfectly detect the various phases of a BDV infection in all species by combining a newly discovered test parameter, the circulating immune...
6379699 Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety  
Complexes are prepared containing two or more different effector molecules joined to each other by a joining component. One effector molecule is a binding molecule such as an antibody or Fc...
6372216 Method of producing specific immunoglobin to block HCV infection  
A drug which protects individuals against hepatitis C virus (HCV) is made of HCV hyperimmune globulins, which guarantee a substantial hyperimmunity against HCV thanks to a substantial...
6365156 Method for improving the half-life of soluble viral-specific ligands on mucosal membranes  
This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal...
6291239 Monoclonal antibody  
A monoclonal antibody (FE8) against human complement receptor type 2 CR2, CD21) which is able to substantially remove C3-derived fragments already attached to CR2, in particular C3dg from CR2 at...
6261806 Molecular sequence of swine retrovirus and methods of use  
This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such...
6228361 IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use  
The present invention provides a human-mouse myeloma analog, designated HMMA 2.11TG/O, which has been deposited with the American Type Culture Collection (ATCC) under Accession Number HB 9583. The...
6187309 Method for treatment of symptoms of central nervous system disorders  
The present invention provides a method for treating the symptoms of autism comprising the step of administering an effective amount of anti-rubeola antibody.
6156314 Chimeric infectious bursal disease virus cDNA clones, expression products and vaccines based thereon  
Chimeric cDNA for the expression of immunogenic polypeptides include the genetic epitopic determinants for a base infectious bursal disease virus strain and at least one other infectious bursal...
RE36866 Anti-aids immunotoxins  
The present invention provides a novel anti-AIDS immunotoxin. The immunotoxin comprises a toxin chemically conjugated to a monoclonal antibody directed against viral reverse transcriptase. Also...
6099840 Hepatitis B vaccine  
A variant HBsAg protein of fragment thereof displaying the antigenicity of Hepatitis B virus surface antigen is disclosed, in which the variant protein or fragment thereof (vHBsAg) comprises a...
6093548 Detection and quantitation of MN-specific antibodies.  
A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and recombinant proteins are provided....
6071516 Treatment of Post-Polio Syndrome with gamma-globulin  
A method for treating a patient suffering from Post-Polio Syndrome (PPS) comprises the intravenous, intramuscular or subcutaneous administration of a pharmacologically effective amount of an...
Matches 1 - 50 out of 97 1 2 >